Moleculomics

Moleculomics launches the Human3DProteome platform

Will Krawszik — Mon, 18 Sep 2017 10:24:32 +0000

Moleculomics has launched its flagship in silico drug discovery platform, Human3DProteome.

Human3DProteome is a comprehensive platform for whole system drug discovery, drug repurposing and toxicity screening.

Human3DProteome is a breakthrough technology for rapid discovery of better and safer drug compounds – a comprehensive in silico platform of the entire human proteome (all the receptors,

The post Moleculomics launches the Human3DProteome platform appeared first on Moleculomics.

NC3Rs CRACK IT Solution: Cross-species comparative in silico platform (CRISP)

Will Krawszik — Fri, 26 May 2017 20:33:14 +0000

Moleculomics has gained the support of the NC3Rs through the development of a CRACK IT Solution; A technology partnering hub to accelerate the translation of technologies with 3Rs potential (‘Solutions’) by helping to identify new partners and customers to use, develop and validate the technology. As such, a collaborative opportunity is presented to help validate their CRISP comparative in silico structural/ functional platform that identifies species differences in liver activity,

The post NC3Rs CRACK IT Solution: Cross-species comparative in silico platform (CRISP) appeared first on Moleculomics.

In silico drug discovery software platform for the UK Ministry of Defence

Will Krawszik — Sun, 07 May 2017 23:59:07 +0000

A spin out company of the Institute of Life Science at Swansea University has recently delivered an in silico drug discovery software platform for the UK Ministry of Defence.

The software tool named TargetPath, developed for the identification of protein antibiotic or anti-bacterial target(s) within a pathogen, will be used by the scientists of Defence,

The post In silico drug discovery software platform for the UK Ministry of Defence appeared first on Moleculomics.

Spin-out company helps get effective drugs to market, more quickly and cheaply

Will Krawszik — Sun, 07 May 2017 23:37:07 +0000

Getting better drugs to market faster, and at a fraction of the cost, is a step closer thanks to technology for speeding up the testing process, which is being developed by a Swansea University spin-out company, Moleculomics.

The company has been developing comprehensive platforms of computer-generated models for protein structures in the human body.

The post Spin-out company helps get effective drugs to market, more quickly and cheaply appeared first on Moleculomics.

The British Yeast Group Meeting 2016

Will Krawszik — Mon, 14 Nov 2016 20:48:25 +0000

The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.

During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts.

The post The British Yeast Group Meeting 2016 appeared first on Moleculomics.

Moleculomics Sponsors the British Science Festival 2016

Will Krawszik — Tue, 08 Nov 2016 21:56:41 +0000

Moleculomics were proud to sponsor the 2016 British Science Festival, hosted by Swansea University this year.

The British Science Festival is Europe’s longest-standing national event which connects people with scientists, engineers, technologists and social scientists. Organised by the British Science Association (BSA), the event was first held in York in 1831 and then annually at cities across the UK.

The post Moleculomics Sponsors the British Science Festival 2016 appeared first on Moleculomics.

Proteome scale structural bioinformatics platforms in drug discovery

Will Krawszik — Tue, 01 Nov 2016 22:02:03 +0000

Moleculomics founder and CEO Dr Jonathan Mullins was proud to be invited as keynote speaker at the International conference on Clinical Sciences and Drug Discovery (CSDD-2016) in Dundee earlier this year.

Highly aligned to the evolution of Moleculomics, the focus of CSDD-2016 lies in the translation of academic research findings into industry-driven drug development.

The post Proteome scale structural bioinformatics platforms in drug discovery appeared first on Moleculomics.

Moleculomics is recruiting: Bioinformatician Research Assistant

Will Krawszik — Wed, 06 Jul 2016 21:39:54 +0000

JOB: Bioinformatician Research Assistant

LOCATION: Laval, Quebec ⧉

JOB TERM: 1 years fixed term with opportunity for continuation

Moleculomics is seeking to employ a bioinformatician for the delivery of a strategically important project for the development of our fast growing company.

In this role you will be responsible for the technical delivery of a project spanning both high throughput protein structural modelling and predicted interaction of resulting protein structures with large libraries of small molecules.

The post Moleculomics is recruiting: Bioinformatician Research Assistant appeared first on Moleculomics.

Moleculomics Identify Novel Host-Pathogen Interaction Drug Targets

Will Krawszik — Fri, 06 May 2016 22:01:14 +0000

Moleculomics, a company who specialise in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel therapies to meet the UK’s current and future defence and security needs.

The post Moleculomics Identify Novel Host-Pathogen Interaction Drug Targets appeared first on Moleculomics.

Moleculomics Announces New Sales and Customer Support Office in Montreal

Will Krawszik — Thu, 03 Mar 2016 15:00:49 +0000

Montreal, Canada, March 3, 2016 – Moleculomics, a UK university spin-out company offering powerful high-throughput prediction of small molecule – protein interactions using cutting-edge in silico modelling and screening tools, is pleased to announce the official opening of its North American sales and support office within the NEOMED Institute in Laval,

The post Moleculomics Announces New Sales and Customer Support Office in Montreal appeared first on Moleculomics.